Literature DB >> 11861806

Prevention of antibody-mediated elimination of ligand-targeted liposomes by using poly(ethylene glycol)-modified lipids.

Wai Ming Li1, Lawrence D Mayer, Marcel B Bally.   

Abstract

One of the major obstacles in the development of ligand-targeted liposomes is poor liposome circulation longevity as a result of antibody-mediated elimination of these highly immunogenic carriers. Because studies from our laboratory suggest that it is not possible to reduce the immunogenicity of ligand-conjugated liposomes by using surface-grafted poly(ethylene glycol) (PEG), we investigated the usefulness of PEG in protecting hapten-conjugated liposomes from elimination by an existing immune response that was previously established against the hapten. Using biotin as a model hapten, a strong biotin-specific antibody response was generated in mice by using bovine serum albumin-biotin. When these animals were challenged with liposomes containing biotin-conjugated lipid (1 or 0.1%), these liposomes were rapidly eliminated. Incorporation of PEG-lipids into these liposomes substantially reduced biotin-specific antibody binding as measured using an in vitro antibody consumption assay. However, depending on the hapten concentration, significant reductions in antibody binding through the use of PEG-lipids may not be sufficient to protect these liposomes from rapid elimination in vivo. Complete protection of liposomes was only achieved when the biotin concentration on liposome surface was low (0.1%) and with 5 mol% of either 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-n-[methoxy(polyethylene glycol)-2000] or 1,2-dipalmatoyl-sn-glycero-3-phosphoethanolamine-n-methoxy(polyethylene glycol)-2000]. The use of 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-n-[methoxy(polyethylene glycol)-2000] (up to 15 mol%) was not effective in protecting liposomes from rapid elimination in vivo, indicating the limited usefulness of this highly exchangeable PEG-lipid. In conclusion, our in vivo and in vitro data indicate that liposomes can be protected from antibody-mediated elimination by using the right type and concentration of PEG-lipids. This result has important implication in the development of ligand-targeted liposomes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11861806     DOI: 10.1124/jpet.300.3.976

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

1.  Transfection efficiency of pORF lacZ plasmid lipopolyplex to hepatocytes and hepatoma cells.

Authors:  Xun Sun; Hong-Wei Zhang; Zhi-Rong Zhang
Journal:  World J Gastroenterol       Date:  2004-02-15       Impact factor: 5.742

Review 2.  Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics.

Authors:  Long Xu; Thomas Anchordoquy
Journal:  J Pharm Sci       Date:  2011-01       Impact factor: 3.534

3.  Targeting of tumor-associated macrophages made possible by PEG-sheddable, mannose-modified nanoparticles.

Authors:  Saijie Zhu; Mengmeng Niu; Hannah O'Mary; Zhengrong Cui
Journal:  Mol Pharm       Date:  2013-08-06       Impact factor: 4.939

4.  Accumulation, internalization and therapeutic efficacy of neuropilin-1-targeted liposomes.

Authors:  Eric E Paoli; Elizabeth S Ingham; Hua Zhang; Lisa M Mahakian; Brett Z Fite; M Karen Gagnon; Sarah Tam; Azadeh Kheirolomoom; Robert D Cardiff; Katherine W Ferrara
Journal:  J Control Release       Date:  2014-01-13       Impact factor: 9.776

5.  Biological evaluation of liposome-encapsulated hemoglobin surface-modified with a novel PEGylated nonphospholipid amphiphile.

Authors:  Vivek R Yadav; Okhil Nag; Vibhudutta Awasthi
Journal:  Artif Organs       Date:  2014-04-22       Impact factor: 3.094

Review 6.  Sheddable coatings for long-circulating nanoparticles.

Authors:  Birgit Romberg; Wim E Hennink; Gert Storm
Journal:  Pharm Res       Date:  2007-06-06       Impact factor: 4.200

7.  Passive transfer of polyethylene glycol to liposomal-recombinant human FVIII enhances its efficacy in a murine model for hemophilia A.

Authors:  Karthik Ramani; Vivek Purohit; Razvan Miclea; Puneet Gaitonde; Robert M Straubinger; Sathy V Balu-Iyer
Journal:  J Pharm Sci       Date:  2008-09       Impact factor: 3.534

8.  Decreased nonspecific adhesivity, receptor-targeted therapeutic nanoparticles for primary and metastatic breast cancer.

Authors:  Jimena G Dancy; Aniket S Wadajkar; Nina P Connolly; Rebeca Galisteo; Heather M Ames; Sen Peng; Nhan L Tran; Olga G Goloubeva; Graeme F Woodworth; Jeffrey A Winkles; Anthony J Kim
Journal:  Sci Adv       Date:  2020-01-15       Impact factor: 14.136

Review 9.  Molecular Simulations of PEGylated Biomolecules, Liposomes, and Nanoparticles for Drug Delivery Applications.

Authors:  Hwankyu Lee
Journal:  Pharmaceutics       Date:  2020-06-10       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.